|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CASC2 acts as a tumor suppressor in human malignancies serving as a ceRNA for miRNAs; Sprouty2 (SPRY2), a key antagonist of RTK signaling, also serves as a tumor suppressor.
|
29373811 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treatment resistance.
|
29540470 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, SPRY2 overexpression promoted tumor propagation of low-tumorigenic U251 cells.
|
29635363 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The dissection of the mechanism of action of SPRY2 in colon cancer cells is important to understand the upregulation of this gene in a subset of patients with this neoplasia that have poor prognosis.
|
26455323 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study reveals that SPRY2 acts as a tumor suppressor in human ovarian cancer and illustrates the underlying mechanisms that can be used as possible targets for the development of novel therapeutics.
|
27835572 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SPRY2, counter to its roles in other cancer settings, promotes glioma cell and tumor growth and cellular resistance to targeted inhibitors of oncogenic RTKs, thus making SPRY2 and the cell signaling processes it regulates potential novel therapeutic targets in glioma.
|
25934697 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sprouty2 (SPRY2) has been known as a tumor suppressor by blocking both ERK and AKT signaling cascades.
|
25935347 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sprouty2 (SPRY2) has been known as a tumor suppressor by preventing both ERK and AKT signaling activations.
|
26265114 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these results show that loss of Pten cooperates with Spry2 deficiency by bypassing a novel tumor suppressor checkpoint.
|
23434594 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also measured the expression level of Spry2 in 103 archived RCC tissues by immunohistochemical staining and found its correlation with clinicopathologic findings such as tumor size (P = .002), pathologic TNM stage (P <.001), tumor grade (P <.001), lymph node metastasis (P = .001), distant metastasis (P <.001), and poor survival (P = .001).
|
23688375 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Down-regulation of Spry2 was associated with highly malignant phenotypes like vascular invasion and advanced tumor stages, and was positively correlated with the metastatic potential of HCC cell lines.
|
22484587 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sprouty2 (Spry2) was identified recently as a tumor suppressor gene in cancer cells which inhibits the activation of receptor tyrosine kinases (RTKs).
|
22322462 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results show that Spry2 was downregulated in human colon cancer, and its expression levels were lower in advanced-stage tumors than in early-stage tumors.
|
21099344 |
2011 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We examined DNA methylation patterns in TCL1-tg B-cell tumors to discover tumor-associated epigenetic changes, and identified hypermethylation of sprouty2 (Spry2).
|
19147787 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our study provides evidence that inhibition of Spry activity cooperates with other oncogenes to promote liver cancer in mouse models, and Spry2 may function as a candidate tumor suppressor for HCC development in vivo.
|
18214995 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nude mice inoculated with HT mock cells developed tumors seven times larger than those from HT-hSpry2-transfected cells.
|
18427547 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A similar, but less pronounced, effect in tumor formation was observed when Spry2 was down-regulated in human patient-derived fibrosarcoma cell lines.
|
18048363 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that Spry2 plays a role as tumor suppressor in NSCLC by antagonizing receptor tyrosine kinase-induced signaling at different levels, indicating feasibility for the usage of Spry in targeted gene therapy of NSCLC.
|
17510316 |
2007 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
In contrast to previous studies of Spry2 down-regulation in other cancers, we have ruled out loss of heterozygosity or the methylation of promoter sites, two common mechanisms responsible for the silencing of genes with tumor suppressor properties.
|
16489004 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We therefore propose hSPRY2 as a potential tumour suppressor locus in CaP.
|
15735753 |
2005 |